Table 3.
Anthropometric and biochemical parameters of Non-Responders (NR) and Responders (R) at the second phase of the study.
|
NR (n = 10) Baseline |
R (n = 10) Baseline/SST |
R HDS |
p1 | p2 | |
|---|---|---|---|---|---|
| Age(y) | 62.7 ± 2.0 | 62.1 ± 2.4 | – | – | – |
| Gender (M/F), n | 4/6 | 3/7 | – | – | – |
| Atorvastatin (20; 40; 80 mg) | 1; 2;0 | 1; 1;1 | – | – | – |
| Sinvastatin (20; 40) | 3; 4 | 4; 3 | – | – | – |
| Weight (kg) | 86.0 ± 11.0 | 75.9 ± 5.6 | 76.9 ± 5.8 | 0.526 | 0.939 |
| BMI (kg/m2) | 32.0 ± 2.5 | 29.5 ± 1.8 | 29.9 ± 1.8 | 0.526 | 0.879 |
| Waist circunference (cm) | 99.7 ± 6.6 | 91.9 ± 4.3 | 93.0 ± 4.3 | 0.407 | 0.879 |
| Abdominal circunference (cm) | 106.3 ± 5.6 | 98.9 ± 3.6 | 96.8 ± 3.5 | 0.661 | 0.650 |
| Hip circunference (cm) | 114.0 ± 5.8 | 104.8 ± 3.4 | 106.0 ± 3.5 | 0.306 | 0.677 |
| Glucose (mg/dL) | 115.8 ± 11.9 | 121.5 ± 17.1 | 121.6 ± 6.5 | 0.910 | 0.174 |
| Total cholesterol (mg/dL) | 178.4 ± 9.9 | 210.7 ± 19.6 | 196.3 ± 12.7 | 0.241 | 0.597 |
| LDL-C (mg/dL) | 101.9 ± 8.7 | 117.0 ± 14.7 | 109.0 ± 9.5 | 0.762 | 0.791 |
| HDL-C (mg/dL) | 43.4 ± 3.2 | 61.3 ± 6.1 | 62.6 ± 5.6 | 0.031 | 0.939 |
| VLDL-C (mg/dL) | 33.1 ± 4.9 | 32.4 ± 6.6 | 24.7 ± 2.0 | 0.850 | 0.427 |
| TG (mg/dL) | 215.8 ± 45.2 | 165.3 ± 50.2 | 114.7 ± 14.6 | 0.162 | 0.623 |
| hs-CRP (mg/L) | 2.2 ± 0.4 | 3.4 ± 0.91 | 2.6 ± 0.8 | 0.521 | 0.791 |
| Total HDL particle (μM) | 19.5 ± 0.8 | 22.6 ± 1.4 | 23.0 ± 1.8 | 0.104 | 0.850 |
| Extra Small HDL particle (μM) | 1.4 ± 0.1 | 1.4 ± 0.1 | 1.5 ± 0.2 | 0.910 | 0.969 |
| Small HDL particle (μM) | 6.6 ± 0.8 | 4.7 ± 0.8 | 4.4 ± 0.7 | 0.045 | 0.733 |
| Total small (xs + s) HDL particle (μM) | 7.9 ± 0.7 | 6.2 ± 0.7 | 5.9 ± 0.7 | 0.064 | 0.623 |
| Medium HDL particle (μM) | 8.5 ± 0.6 | 10.6 ± 1.1 | 11.5 ± 1.5 | 0.121 | 0.850 |
| Large HDL particle (μM) | 3.1 ± 0.3 | 5.8 ± 0.9 | 5.5 ± 0.7 | 0.064 | 0.969 |
| Total Cholesterol Efflux Capacity (CEC %) | 11.6 ± 0.4 | 13.8 ± 1.2 | 13.2 ± 1.2 | 0.241 | 0.623 |
| Non-ABCA1 specific CEC (%) | 7.3 ± 0.3 | 8.7 ± 0.6 | 8.7 ± 0.5 | 0.076 | 0.969 |
| ABCA1 specific CEC (%) | 4.4 ± 0.3 | 5.1 ± 0.7 | 4.5 ± 0.6 | 0.623 | 0.570 |
Values are expressed as mean ± SEM. p1: probability value obtained by Mann–Whitney U test of baseline values between NR and R. p2: probability value obtained by Wilcoxon test between standard statin therapy (baseline; SST) and half dose statin with supplements (HDS), for responders only.
Bold font indicates statistically significant p values.